citations

                    Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
                

Authors:

Daniela Weiskopf, Katharina S. Schmitz, Matthijs P. Raadsen, Alba Grifoni, Nisreen M.A. Okba, Henrik Endeman, Johannes P.C. van den Akker, Richard Molenkamp, Marion P.G. Koopmans, Eric C.M. van Gorp, Bart L. Haagmans, Rik L. de Swart, Alessandro Sette & Rory D. de Vries

In:

Source: Science
Publication Date: (2020)
Issue: 5: 48

Research Area:

Immunotherapy / Hematology

Respiratory Research

Cells used in publication:

T cell, human peripheral blood unstim.: Species: human; Tissue Origin: blood
T cell, human stim.: Species: human; Tissue Origin: blood

Experiment

Upon use, PBMC were thawed in IMDM (Lonza, Belgium) supplemented with 10% FBS, 100 IU of penicillin/ml, 100 µg of streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (I10F medium).

PBMC were plated in 96-wells U bottom plates at 1 x 106 PBMC per well in RPMI1640 (Lonza, Belgium) supplemented with 10% human

serum, 100 IU of penicillin/ml, 100 µg of streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (R10H medium) and subsequently stimulated with the

described CD4 and CD8 SARS-CoV-2 MPs at 1µg/ml.

Abstract

COVID-19 is associated with lymphopenia and ‘cytokine storm’, but no information is available on specific cellular immune responses to SARS-CoV-2. Here, we

characterized SARS-CoV-2-specific CD4+ and CD8+ T-cells in patients with acute respiratory distress syndrome. The spike protein (S) proved a potent T-cell antigen

and specific T-cells predominantly produced Th1 cytokines. These novel data are important in vaccine design and will facilitate evaluation of vaccine candidate

immunogenicity.

Open in PubMed